Leerink reiterates Eli Lilly stock rating on obesity drug approval

The reiteration of Eli Lilly’s (LLY) rating by Leerink acts as institutional confirmation of the recent FDA approval tailwinds, reinforcing a fundamental growth narrative that clashes with the stock's current technical "oversold" status. With an RSI of 22.97, LLY is deep in oversold territory, suggesting the recent price decay is likely disconnected from the underlying positive sentiment, presenting a classic mean-reversion opportunity. The MACD crossover (bullish) provides early evidence of a trend reversal, though traders should wait for price stabilization above the $950 psychological resistance level before scaling into new long positions. Fundamental analysis from recent filings suggests that aggressive M&A activity (Centessa/InSilico) is priced in, yet the commercial viability of the newly approved oral obesity pill provides a significant catalyst for top-line expansion that the market has not yet fully priced in during the recent pullback. Given the current 1.17x volume, watch for a breakout above the $965 level; failure to reclaim this zone may lead to further consolidation near the $910 support shelf.